Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice

Blood Cancer Journal

Volumn 6, Issue 6, 2016, Pages

  Liu, X ^a   Barrett, D M ^b   Jiang, S ^a   Fang, C ^a   Kalos, M ^a,c   Grupp, S A ^b   June, C H ^a   Zhao, Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BISPECIFIC T CELL ENGAGER; BLINATUMOMAB; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; ONCOPROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; T CELL CULTURE; T LYMPHOCYTE; TARGET CELL; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL THERAPY; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; LEUKEMIA; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LYMPHOCYTE ACTIVATION; MICE; ONCOGENE PROTEINS, FUSION; RECEPTORS, ANTIGEN; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973365059     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2016.38     Document Type: Article

References (40)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
2. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38.
3. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-528.
4. Uttenthal BJ, Chua I, Morris EC, Stauss HJ. Challenges in T cell receptor gene therapy. J Gene Med 2012; 14: 386-399.
5. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G et al. Mesothelinspecific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2: 112-120.
6. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 22: 1575-1586.
7. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013; 24: 717-727.
8. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70: 9053-9061.
9. Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 2014; 16: 619-630.
10. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
11. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226-6233.
12. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17: 385-392.
13. Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015; 23: 171-178.
14. Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14: 380-388.
15. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332-342.
16. Zhao Y, Boczkowski D, Nair SK, Gilboa E. Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 2003; 102: 4137-4142.
17. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 2015; 75: 3596-3607.
18. Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, McCarthy C et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 2004; 285: 25-40.
19. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 7021-7025.
20. Mehlhop-Williams ER, Bevan MJ. Memory CD8+ T cells exhibit increased antigen threshold requirements for recall proliferation. J Exp Med 2014; 211: 345-356.
21. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115: 98-104.
22. Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 2013; 27: 35-53.
23. Compte M, Cuesta AM, Sanchez-Martin D, Alonso-Camino V, Vicario JL, Sanz L et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009; 27: 753-760.
24. Blanco B, Holliger P, Vile RG, Alvarez-Vallina L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070-1077.
25. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2014; 2: 1059-1070.
26. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov 2015; 5: 1282-1295.
27. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10: 294-298.
28. Breart B, Lemaitre F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 2008; 118: 1390-1397.
29. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121: 4746-4757.
30. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703.
31. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014; 32: 798-808.
32. Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGEA3 induce antitumor immune responses in cancer patients. Blood 2009; 113: 1651-1660.
33. Russo V, Cipponi A, Raccosta L, Rainelli C, Fontana R, Maggioni D et al. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J Clin Invest 2007; 117: 3087-3096.
34. Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol 2015; 33: 1079-1086.
35. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626.
36. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16: 2646-2655.
37. Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184: 452-465.
38. Powell Jr DJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105: 241-250.
39. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumorinfiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34: 236-250.
40. Jayasekara PS, Barrett MO, Ball CB, Brown KA, Hammes E, Balasubramanian R et al. 4-Alkyloxyimino derivatives of uridine-5′-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptors. J Med Chem 2014; 57: 3874-3883.